Fipamezole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Fipamezole
Accession Number
DB06585
Description
Not Available
Type
Small Molecule
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Structure
Thumb
Weight
Average: 230.286
Monoisotopic: 230.121926654
Chemical Formula
C14H15FN2
Synonyms
  • Fipamezole
External IDs
  • JP-1730

Pharmacology

Indication

Investigated for use/treatment in parkinson's disease and neurologic disorders.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
T5RCK09KHV
CAS number
150586-58-6
InChI Key
KXSUAWAUCNFBQJ-UHFFFAOYSA-N
InChI
InChI=1S/C14H15FN2/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14/h3-5,8-9H,2,6-7H2,1H3,(H,16,17)
IUPAC Name
4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
SMILES
CCC1(CC2=CC=C(F)C=C2C1)C1=CNC=N1

References

General References
Not Available
ChemSpider
184735
BindingDB
50417007
ChEMBL
CHEMBL1255582

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentParkinson's Disease (PD)2
2Unknown StatusTreatmentMultiple System Atrophy (MSA) / Parkinson's Disease (PD) / Symptomatic Neurogenic Orthostatic Hypotension (NOH)1
Not AvailableCompletedNot AvailableParkinson's Disease (PD)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP3.56ALOGPS
logP3.56ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.35ChemAxon
pKa (Strongest Basic)6.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.68 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity65.46 m3·mol-1ChemAxon
Polarizability24.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on March 19, 2008 10:38 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates